Opportunity ID: 318229

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-19-312
Funding Opportunity Title: Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 – Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.859 — Biomedical Research and Research Training
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jul 10, 2019
Last Updated Date: Jul 10, 2019
Original Closing Date for Applications: Sep 28, 2021
Current Closing Date for Applications: Sep 28, 2021
Archive Date: Nov 03, 2021
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. see funding announcement for the eligibility details

Additional Information

Agency Name: National Institutes of Health
Description: The National Institute of General Medical Sciences (NIGMS) invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution’s biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for NIH individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH. The goal of this FOA is to support existing COBRE Phase 1 Centers by further strengthening the research infrastructure and to continue the development and support of a critical mass of investigators with the expertise in the Center’s scientific interest areas.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-312.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-E Use for due dates on or before May 24, 2020 PKG00252831 Aug 30, 2019 May 24, 2020 View
FORMS-F Use for due dates on or before January 24, 2022 PKG00258977 Aug 30, 2019 Jan 24, 2022 View

Package 1

Mandatory forms

318229 RR_SF424_2_0-2.0.pdf

318229 PHS398_CoverPageSupplement_4_0-4.0.pdf

318229 RR_OtherProjectInfo_1_4-1.4.pdf

318229 PerformanceSite_2_0-2.0.pdf

318229 RR_KeyPersonExpanded_2_0-2.0.pdf

318229 PHS398_ResearchPlan_4_0-4.0.pdf

Optional forms

318229 PHS_Additional_IndirectCosts-1.0.pdf

318229 PHS_AssignmentRequestForm_2_0-2.0.pdf

Package 2

Mandatory forms

318229 RR_SF424_2_0-2.0.pdf

318229 PHS398_CoverPageSupplement_5_0-5.0.pdf

318229 RR_OtherProjectInfo_1_4-1.4.pdf

318229 PerformanceSite_2_0-2.0.pdf

318229 RR_KeyPersonExpanded_2_0-2.0.pdf

318229 PHS398_ResearchPlan_4_0-4.0.pdf

318229 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

318229 PHS_Additional_IndirectCosts-1.0.pdf

318229 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T20:44:11-05:00

Share This Post, Choose Your Platform!

About the Author: